|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. LSE (The London School of Economics and Political Science). 2010. Policies and incentives for promoting innovation in antibiotic research. http://www2.lse.ac.uk/newsAndMedia/news/archives/2009/09/antibiotics.aspx (accessed March 14, 2010). Matheny, J., M. Mair, and B. Smith. 2008. Cost/success projections for U.S. biodefense counter-measure development. Nature Biotechnology 26(9):981–983. Melese, T., S. M. Lin, J. L. Chang, and N. H. Cohen. 2009. Open innovation networks between academia and industry: An imperative for breakthrough therapies. Nature Medicine 15:502–507. NBSB (National Biodefense Science Board). 2010a. Where are the Countermeasures? Protecting America’s Health From CBRN Threats. http://www.hhs.gov/aspr/barda/documents/phemceimplplan_041607final.pdf (accessed May 17, 2010). NBSB. 2010b. Optimizing industrial involvement in medical countermeasure development. http://www.hhs.gov/aspr/omsph/nbsb/nbsbrpt-2010.pdf (accessed March 2, 2010). PhRMA. 2010. R&D investment by U.S. biopharmaceutical companies remains strong despite ongoing economic challenges. http://www.phrma.org/news/news/rd_investment_us_biopharmaceutical_companies_remains_strong_despite_ongoing_economic_chall (accessed March 30, 2010) Wolf, M. C., A. N. Freiberg, T. Zhang, A. Akyol-Ataman, A. Grock, et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences 107(7):3157–3162.
|
|
|||||||||||||||
